ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS

Core Viewpoint - Oramed Pharmaceuticals Inc. has adopted a Rights Agreement to protect stockholders in the event of a hostile takeover, ensuring fair treatment and enhancing negotiation power with potential acquirers [1][3]. Group 1: Rights Agreement Details - The Rights Agreement, effective November 17, 2025, grants stockholders one common stock purchase right for each share held, aimed at preventing unfair takeover tactics [1][2]. - Each Right allows stockholders to purchase one share of Common Stock at a price of $10.00, becoming exercisable if a person or group acquires 15% or more of the outstanding shares [2][3]. - The Rights will expire three years after adoption unless redeemed or exchanged earlier by the Company [4]. Group 2: Rights Exercise and Redemption - Upon triggering the ownership threshold, each Right can be exercised for shares or equivalent value, but Rights held by the triggering person will become void [3]. - The Board of Directors retains the option to redeem the Rights at $0.012 per Right before any person becomes an Acquiring Person [2][3]. Group 3: Dividend Distribution - The dividend distribution of the Rights will be payable on November 27, 2025, to stockholders of record as of the close of business on that date [4]. - The distribution of Rights is not taxable to stockholders [4]. Group 4: Company Overview - Oramed Pharmaceuticals Inc. is a pioneer in oral delivery solutions for drugs typically administered via injection, utilizing its Protein Oral Delivery (POD™) technology to enhance drug absorption [5].